GILD News and Press, Gilead Sciences Inc. From 04/19/24

2024-04-19 06:13:03 ET More on Bristol-Myers Squibb, Gilead, etc. Johnson & Johnson: Buy This Bargain Before It's Gone Bristol-Myers Squibb: Market Pessimism Won't Last Forever Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript FDA approves Alvo...

2024-04-18 13:59:29 ET Summary Caribou Biosciences, Inc. is expected to produce results from phase 1 ANTLER study, using CB-010 for the treatment of 2nd-line large B-cell lymphoma patients, at medical meeting Q2 of 2024. Initial dose escalation data from the phase 1 ANTLER study i...

NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report , which uses the ESG framework to highlight the successes and achievements of the prior year. In this year's report, you will see examples of Gilead's imp...

2024-04-18 13:26:18 ET Summary ALX Oncology's main focus is the CD47 blocker evorpacept, which has shown encouraging results in combination with other therapies for various cancers. The company has a strong financial position with enough runway to fund operations into early 2026. ...

2024-04-18 10:39:58 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals: Advancing On Several Key Fronts Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript Mirum Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Mirum&#x...

2024-04-17 07:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. U.S. equities continue...

2024-04-16 09:15:50 ET Summary PFE's dividend has reached the sky-high (for a biotech) ~6% mark. Are the dividend and recent share price decline enough to make PFE an attractive play? PFE is following a similar trajectory to GILD in its post-HCV stagnation. PFE may be wort...

2024-04-12 10:46:47 ET More on iShares Russell 1000 Growth ETF: IWF ETF: Solid Track Record, But Looks Overextended Now Stocks with the least price swings, most attractive option-sale candidates - JPM 10 Attractive sell puts within the Russell 1000 - JPM Seek...

2024-04-12 05:11:48 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-04-11 13:51:45 ET More on iShares Russell 1000 Growth ETF: IWF ETF: Solid Track Record, But Looks Overextended Now Attractive call overwriting opportunities for Russell 1000 stocks - JPM The top stocks with selling pressure across the Russell universe - Jefferie...